Clinical Trials in East Greenwich, Rhode Island
20 recruiting
Showing 1–20 of 20 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled296 locationsNCT06419374
Recruiting
Phase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Acute Treatment of Migraine
Pfizer600 enrolled64 locationsNCT04743141
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled342 locationsNCT06318169
Recruiting
Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pediatric Migraine
Pfizer2,100 enrolled109 locationsNCT04649242
Recruiting
Phase 3
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
Lyme Disease
Pfizer1,712 enrolled22 locationsNCT07500506
Recruiting
Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Obesity
Kailera1,200 enrolled32 locationsNCT07284979
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Menstrual Migraine
Pfizer723 enrolled122 locationsNCT06641466
Recruiting
Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Cardiovascular Disease
Amgen11,000 enrolled243 locationsNCT07136012
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Diabetic peripheral neuropathic pain
Vertex Pharmaceuticals Incorporated1,100 enrolled76 locationsNCT06628908
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Diabetic peripheral neuropathic pain
Vertex Pharmaceuticals Incorporated734 enrolled65 locationsNCT07231419
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 2
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
Diabetic peripheral neuropathic pain
Vertex Pharmaceuticals Incorporated300 enrolled47 locationsNCT06619860
Recruiting
Phase 2
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
Type 2 Diabetes
Housey Healthcare ULC300 enrolled25 locationsNCT07546929
Recruiting
Phase 3
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
Influenza
ModernaTX, Inc.4,000 enrolled36 locationsNCT07496450
Recruiting
Phase 4
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
ModernaTX, Inc.30,000 enrolled150 locationsNCT07266558
Recruiting
Phase 3
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Weight Loss
Viking Therapeutics, Inc.1,100 enrolled134 locationsNCT07104383
Recruiting
Phase 2
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
Migraine
AbbVie488 enrolled54 locationsNCT06602479
Recruiting
Phase 3
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
Irritable Bowel Syndrome With Constipation (IBS-C)
Ardelyx180 enrolled41 locationsNCT05643534
Recruiting
Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
COVID-19
BioNTech SE25,500 enrolled208 locationsNCT07300839
Recruiting
Phase 2Phase 3
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
BioNTech SE4,292 enrolled134 locationsNCT05543616